Clinton Yam, MD

M.D. Anderson Cancer Center

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers in breast cancer

PubMed author-name match

Trials

Studies that name Clinton Yam, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:48 UTC. Open this list on ClinicalTrials.gov

Ph2
NCT07610525 · Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial
M.D. Anderson Cancer Center · not yet recruiting · Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy · principal investigator
Ph1/Ph2
NCT07011654 · Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center · recruiting · Metastatic Triple-Negative Breast Cancer · principal investigator
Ph2
NCT05675579 · A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center · active not recruiting · Breast Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name in breast cancer.